Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283463715> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4283463715 endingPage "154" @default.
- W4283463715 startingPage "154" @default.
- W4283463715 abstract "Bronchopulmonary dysplasia is a common pathology of premature newborns caused by oxidative stress and mechanical ventilation, resulting in hypoalveolization and impaired angiogenesis. It can be complicated by pulmonary hypertension (HTP-DBP) with excess mortality. Celastrol has anti-inflammatory and antioxidant properties. So, we addressed its potential therapeutic interest in HTP-DBP. Different concentrations of celastrol were used in a murine model of hyperoxic HTP-DBP (14 days with 90% O2) and we evaluated hemodynamic parameters with echocardiography and lung remodeling with histological methods. Pulmonary arterial (PA) reactivity was addressed with myograph. Cytoplasmic calcium (Ca2 + i) response to endothelin-1 (ET-1) was evaluated in human fetal PA smooth muscle cells (fPASMC) with spectrophotometry in normoxic (21% O2) and hyperoxic conditions (48 h with 60% O2). Inflammation was addressed with IL6 ELISA assay in fPASMC. Celastrol reduces mortality at doses of 1 and 0.5 mg/kg/d compared to the hyperoxic control group. At 1 mg/kg/d, it normalizes PAAT (PA acceleration time) (P < 0.001) and reduces vascular hyperreactivity to phenylephrine and ET-1 (P < 0.001) with no effect on the alteration of the response to acetylcholine induced by hyperoxia. At doses of 0.1, 0.5 and 1 mg/kg/d, it decreases right heart hypertrophy and vascular remodeling (wall thickness) but has no effect on alveolization and vascular density (vWF staining). Finally, although celastrol (0.1 and 0.3 μM) decreases the increased Ca2 + i response to ET-1 in hyperoxia in fPASMC, expression of ET-1 receptors (Western blotting and qPCR for ET-A and ET-B) was unchanged. However, celastrol 0.5 μM decreases ET-1 concentration measured with an ELISA assay in human umbilical arterial endothelial cells. An increased concentration of IL6 was also observed in fPASMC in hyperoxia and was decreased by celastrol 0.5 μM. Celastrol has a preventive dose-dependent effect on some hallmarks of HTP induced by hyperoxia and could thus be considered as an interesting new potential therapeutic option for HTP-DBP." @default.
- W4283463715 created "2022-06-26" @default.
- W4283463715 creator A5027490680 @default.
- W4283463715 creator A5052695149 @default.
- W4283463715 creator A5060028675 @default.
- W4283463715 creator A5060937292 @default.
- W4283463715 creator A5078424834 @default.
- W4283463715 creator A5081614754 @default.
- W4283463715 creator A5087686495 @default.
- W4283463715 creator A5090687526 @default.
- W4283463715 date "2022-06-01" @default.
- W4283463715 modified "2023-10-01" @default.
- W4283463715 title "Celastrol: A new potential therapeutic option in pulmonary hypertension associated to bronchopulmonary dysplasia" @default.
- W4283463715 doi "https://doi.org/10.1016/j.acvdsp.2022.04.138" @default.
- W4283463715 hasPublicationYear "2022" @default.
- W4283463715 type Work @default.
- W4283463715 citedByCount "0" @default.
- W4283463715 crossrefType "journal-article" @default.
- W4283463715 hasAuthorship W4283463715A5027490680 @default.
- W4283463715 hasAuthorship W4283463715A5052695149 @default.
- W4283463715 hasAuthorship W4283463715A5060028675 @default.
- W4283463715 hasAuthorship W4283463715A5060937292 @default.
- W4283463715 hasAuthorship W4283463715A5078424834 @default.
- W4283463715 hasAuthorship W4283463715A5081614754 @default.
- W4283463715 hasAuthorship W4283463715A5087686495 @default.
- W4283463715 hasAuthorship W4283463715A5090687526 @default.
- W4283463715 hasBestOaLocation W42834637151 @default.
- W4283463715 hasConcept C126322002 @default.
- W4283463715 hasConcept C134018914 @default.
- W4283463715 hasConcept C149601957 @default.
- W4283463715 hasConcept C170493617 @default.
- W4283463715 hasConcept C2777714996 @default.
- W4283463715 hasConcept C2778376644 @default.
- W4283463715 hasConcept C2778721537 @default.
- W4283463715 hasConcept C2779234561 @default.
- W4283463715 hasConcept C2780672939 @default.
- W4283463715 hasConcept C2780930700 @default.
- W4283463715 hasConcept C54355233 @default.
- W4283463715 hasConcept C71924100 @default.
- W4283463715 hasConcept C86803240 @default.
- W4283463715 hasConceptScore W4283463715C126322002 @default.
- W4283463715 hasConceptScore W4283463715C134018914 @default.
- W4283463715 hasConceptScore W4283463715C149601957 @default.
- W4283463715 hasConceptScore W4283463715C170493617 @default.
- W4283463715 hasConceptScore W4283463715C2777714996 @default.
- W4283463715 hasConceptScore W4283463715C2778376644 @default.
- W4283463715 hasConceptScore W4283463715C2778721537 @default.
- W4283463715 hasConceptScore W4283463715C2779234561 @default.
- W4283463715 hasConceptScore W4283463715C2780672939 @default.
- W4283463715 hasConceptScore W4283463715C2780930700 @default.
- W4283463715 hasConceptScore W4283463715C54355233 @default.
- W4283463715 hasConceptScore W4283463715C71924100 @default.
- W4283463715 hasConceptScore W4283463715C86803240 @default.
- W4283463715 hasIssue "2" @default.
- W4283463715 hasLocation W42834637151 @default.
- W4283463715 hasOpenAccess W4283463715 @default.
- W4283463715 hasPrimaryLocation W42834637151 @default.
- W4283463715 hasRelatedWork W1903790012 @default.
- W4283463715 hasRelatedWork W2005609654 @default.
- W4283463715 hasRelatedWork W2109318759 @default.
- W4283463715 hasRelatedWork W2361624960 @default.
- W4283463715 hasRelatedWork W2461343632 @default.
- W4283463715 hasRelatedWork W2488721249 @default.
- W4283463715 hasRelatedWork W2532701723 @default.
- W4283463715 hasRelatedWork W2906088675 @default.
- W4283463715 hasRelatedWork W3194447027 @default.
- W4283463715 hasRelatedWork W4285600180 @default.
- W4283463715 hasVolume "14" @default.
- W4283463715 isParatext "false" @default.
- W4283463715 isRetracted "false" @default.
- W4283463715 workType "article" @default.